References

1. [1]. Kaba   RA., , Ahmed   O., , Cannie   D. . ENGAGE AF: Effective anticoagulation with factor Xa in next generation treatment of atrial fibrillation. . Glob Cardiol Sci Pract . 2013; ;2013: 4 : 354– – 356 .
   [Google Scholar]
2. [2]. Dager   WE., , Gosselin   RC., , Kitchen   S., , Dwyre   D. . Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study. . Ann Pharmacother . 2012 Dec; ;46: 12 : 1627– – 1636 .
   [Google Scholar]
3. [3]. Sarma A. Novel Oral Anticoagulants and Lack of Reversibility. Cardiosource.org. Accessed 1/11/2014 .
4. [4]. Laulicht   B., , Bakhru   S., , Lee   C., , Baker   C., , Jiang   X., , Mathiowitz   E., , Costin   J., , Steiner   S. . Small Molecule Antidote for Anticoagulants. . Circulation . 2012 Nov; ;126: 21S : A11395 .
   [Google Scholar]
5. [5]. Mark   C., , Vandana   M., , Michael   K., , Genmin   L., , Conley   PB., , Stanley   H., , Castillo   J., , Hutchaleelaha   A., , Karbarz   M., , Lin   JP., , Barron   L., , Russell   S., , Levy   GG., , Connolly   S., , Curnutte   JT. . A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy Subjects By Andexanet Alfa (PRT064445), An Antidote For Fxa Inhibitors. . Blood . 2013 Oct; ;122: 21 : 3636 .
   [Google Scholar]